Performance of Neck Imaging Reporting and Data System (NI-RADS) for Diagnosis of Recurrence of Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-analysis

References

1. 1.↵
   1. Wong LY,
   2. Wei WI,
   3. Lam LK, et al

   . Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 2003;25:953–59 doi:10.1002/hed.10310 pmid:14603456

   CrossRefPubMed
2. 2.↵
   1. van Weert S,
   2. Leemans CR

   . Salvage surgery in head and neck cancer. Oral Dis 2021;27:117–24 doi:10.1111/odi.13582 pmid:32738064

   CrossRefPubMed
3. 3.↵
   1. Baba A,
   2. Ojiri H,
   3. Ikeda K, et al

   . Essentials on oncological imaging: postoperative computed tomography and magnetic resonance imaging of oral tongue cancer. Can Assoc Radiol J 2018;69:458–67 doi:10.1016/j.carj.2018.08.001 pmid:30390963

   CrossRefPubMed
4. 4.↵
   1. Strauss SB,
   2. Aiken AH,
   3. Lantos JE, et al

   . Best practices: application of NI-RADS for posttreatment surveillance imaging of head and neck cancer. AJR Am J Roentgenol 2021;216:1438–51 doi:10.2214/AJR.20.23841 pmid:32876470

   CrossRefPubMed
5. 5.↵
   1. Aiken AH,
   2. Rath TJ,
   3. Anzai Y, et al

   . ACR Neck Imaging Reporting and Data Systems (NI-RADS): a white paper of the ACR NI-RADS Committee. J Am Coll Radiology 2018;15:1097–108 doi:10.1016/j.jacr.2018.05.006 pmid:29983244

   CrossRefPubMed
6. 6.↵
   1. Page MJ,
   2. McKenzie JE,
   3. Bossuyt PM, et al

   . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71 doi:10.1136/bmj.n71 pmid:33782057

   CrossRefPubMed
7. 7.↵
   1. Stang A

   . Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–05 doi:10.1007/s10654-010-9491-z pmid:20652370

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Deeks JJ,
   2. Dinnes J,
   3. D'Amico R, et al

   ; European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:iii–x. 1–173 doi:10.3310/hta7270 pmid:14499048

   CrossRefPubMed
9. 9.↵
   1. Hsu D,
   2. Chokshi FH,
   3. Hudgins PA, et al

   . Predictive value of first posttreatment imaging using standardized reporting in head and neck cancer. Otolaryngol Head Neck Surg 2019;161:978–85 doi:10.1177/0194599819865235 pmid:31331239

   CrossRefPubMed
10. 10.↵
    1. Elsholtz FH,
    2. Ro SR,
    3. Shnayien S, et al

    . Impact of double reading on NI-RADS diagnostic accuracy in reporting oral squamous cell carcinoma surveillance imaging: a single-center study. Dentomaxillofac Radiol 2022;51:1–8 doi:10.1259/dmfr.20210168 pmid:34233509

    CrossRefPubMed
11. 11.↵
    1. Wangaryattawanich P,
    2. Branstetter BF,
    3. Ly JD, et al

    . Positive predictive value of neck imaging reporting and data system categories 3 and 4 posttreatment FDG-PET/CT in head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 2020;41:1070–75 doi:10.3174/ajnr.A6589 pmid:32467187

    CrossRefPubMed
12. 12.↵
    1. Jajodia A,
    2. Mandal G,
    3. Yadav V, et al

    . Adding MR diffusion imaging and T2 signal intensity to Neck Imaging Reporting and Data System categories 2 and 3 in primary sites of postsurgical oral cavity carcinoma provides incremental diagnostic value. AJNR Am J Neuroradiol 2022;43:1018–23 doi:10.3174/ajnr.A7553 pmid:35738671

    CrossRefPubMed
13. 13.↵
    1. Kumar I,
    2. Reza SO,
    3. Choudhary S, et al

    . Performance of NI-RADS on CECT alone to predict recurrent head and neck squamous cell carcinoma after chemoradiotherapy: added value of RECIST 1.1. Indian J Radiol Imaging 2022;32:151–58 doi:10.1055/s-0042-1754315 pmid:35924129

    CrossRefPubMed
14. 14.↵
    1. Ashour MM,
    2. Darwish EA,
    3. Fahiem RM, et al

    . MRI posttreatment surveillance for head and neck squamous cell carcinoma: proposed MR NI-RADS criteria. AJNR Am J Neuroradiol 2021;42:1123–29 doi:10.3174/ajnr.A7058 pmid:33707288

    CrossRefPubMed
15. 15.↵
    1. Abdelrahman AS,
    2. Ashour MM,
    3. Abdelaziz TT

    . Predictive value of Neck Imaging Reporting and Data System (NIRADS) in CECT/CEMRI of laryngeal and oral cavity squamous cell carcinoma. Egypt J Radiol Nucl Med 2020;51:241 doi:10.1186/s43055-020-00366-0

    CrossRef
16. 16.↵
    1. Aiken AH,
    2. Hudgins PA

    . Neck Imaging Reporting and Data System. Magn Reson Imaging Clin N Am 2018;26:51–62 doi:10.1016/j.mric.2017.08.004 pmid:29128006

    CrossRefPubMed
17. 17.↵
    1. Lee J,
    2. Kaht D,
    3. Ali S, et al

    . Performance of the Neck Imaging Reporting and Data System as applied by general neuroradiologists to predict recurrence of head and neck cancers. Head Neck 2022;44:2257–64 doi:10.1002/hed.27138 pmid:35801334

    CrossRefPubMed
18. 18.↵
    1. Abdelaziz TT,
    2. Abdel Razk AA,
    3. Ashour MM

    et al. Interreader reproducibility of the Neck Imaging Reporting and Data system (NI-RADS) lexicon for the detection of residual/recurrent disease in treated head and neck squamous cell carcinoma (HNSCC). Cancer Imaging 2020;20:1–10 doi:10.1186/s40644-020-00337-8 pmid:32811559

    CrossRefPubMed
19. 19.↵
    1. Dinkelborg P,
    2. Ro SR,
    3. Shnayien S, et al

    . Retrospective evaluation of NI-RADS for detecting postsurgical recurrence of oral squamous cell carcinoma on surveillance CT or MRI. AJR Am J Roentgenol 2021;217:198–206 doi:10.2214/AJR.20.24209 pmid:32876497

    CrossRefPubMed
20. 20.↵
    1. Elsholtz FH,
    2. Erxleben C,
    3. Bauknecht HC, et al

    . Reliability of NI-RADS criteria in the interpretation of contrast-enhanced magnetic resonance imaging considering the potential role of diffusion-weighted imaging. Eur Radiol 2021;31:6295–304 doi:10.1007/s00330-021-07693-4 pmid:33533989

    CrossRefPubMed
21. 21.↵
    1. Patel LD,
    2. Bridgham K,
    3. Ciriello J, et al

    . PET/MR imaging in evaluating treatment failure of head and neck malignancies: a Neck Imaging Reporting and Data System–based study. AJNR Am J Neuroradiol 2022;43:435–41 doi:10.3174/ajnr.A7427 pmid:35177543

    CrossRefPubMed
22. 22.↵
    1. Baba A,
    2. Kurokawa R,
    3. Kurokawa M, et al

    . Apparent diffusion coefficient for differentiation between benign post-treatment changes and recurrence in head and neck cancer: a systematic review and meta-analysis. AJNR Am J Neuroradiol 2022;43:442–47 doi:10.3174/ajnr.A7431 pmid:35210272

    CrossRefPubMed
23. 23.↵
    1. Baba A,
    2. Kurokawa R,
    3. Kurokawa M, et al

    . Dynamic contrast‐enhanced MRI parameters and normalized ADC values could aid differentiation of skull base osteomyelitis from nasopharyngeal cancer. AJNR Am J Neuroradiol 2022;44:74–78 doi:10.3174/ajnr.A7740 pmid:36521963

    CrossRefPubMed
24. 24.↵
    1. Mishra V,
    2. Singh A,
    3. Chen X, et al

    . Application of liquid biopsy as multi-functional biomarkers in head and neck cancer. Br J Cancer 2022;126:361–70 doi:10.1038/s41416-021-01626-0 pmid:34876674

    CrossRefPubMed
25. 25.↵
    1. Flach S,
    2. Howarth K,
    3. Hackinger S, et al

    . Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Br J Cancer 2022;126:1186–95 doi:10.1038/s41416-022-01716-7 pmid:35132238

    CrossRefPubMed
26. 26.↵
    1. Ioannidis JP

    . The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. Milbank Q 2016;94:485–514 doi:10.1111/1468-0009.12210 pmid:27620683

    CrossRefPubMed